Pharmasset Starts Phase III Trial Of Clevudine

October 2007
Bioworld Week;10/8/2007, Vol. 15 Issue 41, p3
The article reports on the commencement of the Phase III clinical trial of Pharmasset Inc.'s pyrimidine nucleoside analogue Clevudine in the U.S. The company has acquired $1 million as a payment from Korean partner Bukwang Pharmaceutical Co. Ltd. The 48-week evaluation aims to identify the efficacy of the 30 mg of the drug compared to 10 mg dosage of Hepsera.


Related Articles

  • PHARMASSET TO DEVELOP CLEVUDINE FOR HEPATITIS B.  // Worldwide Biotech;Aug2005, Vol. 17 Issue 8, p5 

    Reports on the license agreement of Pharmasset Inc. with Bukwang Pharmaceutical Co. Ltd., to develop and commercialize Clevudine, a treatment for hepatitis B virus infections, as of August 2005. Product details; Terms of the agreement; Background information on Pharmasset.

  • Research & Markets: South Korea Pharmaceuticals and Healthcare Report Q1 2012 -- In 2011, the US Congress Approved the Republic Of Korea-US Free Trade Agreement.  // Biomedical Market Newsletter;12/28/2011, Vol. 21, p1 

    The article presents a report on the impact of the Republic Of Korea-US Free Trade Agreement on pharmaceuticals and healthcare companies in South Korea (SK). It is stated that price reduction by SK will cause problem for pharmaceutical sector. Information about several pharmaceutical companies...

  • Pipeline.  // Pharmaceutical Representative;May2010, Vol. 40 Issue 5, p10 

    This section offers information on various drug clinical trials. The Phase III clinical study of Optimer Pharmaceutical's fidaxomicin drug in patients with Clostridium Difficile Infection (CDI) showed positive results. Pharmasset reported that its Phase IIa study showed the interim efficacy and...

  • All Eyes on HCV as Pharmasset Ends Clevudine Studies in HBV. Boggs, Jennifer // BioWorld Today;4/21/2009, Vol. 20 Issue 75, p1 

    The article reveals that Pharmasset Inc. has decided to drop its late-stage hepatitis B candidate clevudine and to refocus resources to its earlier-stage pipeline aimed at the hepatitis C virus (HCV) space. A number of adverse events associated with clevudine in South Korea prompted the...

  • Pharmasset Amends HCV Trials, Sends Ripples Through Space. Boggs, Jennifer // BioWorld Today;12/19/2011, Vol. 22 Issue 243, p2 

    The article reports that guanine nucleotide analogue PSI-938 has been dropped by Pharmasset Inc. from its Phase IIb trial after discovering laboratory abnormalities associated with liver function in patients receiving the drug. In response to the news, Phamasset shares dropped by 4.04 U.S. dolls...

  • Shares of Pharmasset Soar 45% on HCV Data.  // Bioworld Week;1/14/2008, Vol. 16 Issue 2, p3 

    The article reports on the increase in shares of Pharmasset Inc. after their trial drug, R7128, in combination with Pegasys and Copegus, showed positive results in the treatment of hepatitis C virus (HCV). The preliminary results of the Phase I clinical trials revealed that patients who received...

  • Clevudine trial halted.  // Reactions Weekly;5/2/2009, Issue 1250, p2 

    The article reports on the decision of Pharmasset Inc. to terminate its Phase III QUASH studies of clevudine for the treatment of hepatitis B virus infection. A small number of cases of mild to moderate myopathy or muscle weakness related with increased creatine kinase levels were reported in...

  • New 12 Week, Interferon-Free Treatment Arms Added to All-Oral Combination Study of PSI-7977 and Daclatasvir (BMS-790052) for HCV Genotype 1.  // Biomedical Market Newsletter;11/9/2011, Vol. 21, p298 

    The article reports on the addition of four treatment arms to the ongoing Phase IIa trial evaluating the combination of Pharmasset Inc.'s PSI-7977 and Bristol-Myers Squibb Co.'s daclatasvir (BMS-790052) inhibitors in New Jersey. It cites the data from Pharmasset's trial which demonstrate the...

  • Shares of Pharmasset Soar 44% on Positive Phase I HCV Data. Young, Donna // BioWorld Today;1/8/2008, Vol. 19 Issue 5, p1 

    This article deals with the stock gains posted by Pharmasset Inc. on January 7, 2007 following news of positive preliminary results of its clinical trial of a combined therapy for hepatitis C virus (HCV). The trial involved Pharmasset's R7128 and combined with pegylated interferon and ribavirin....


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics